EP0526452B2 — Hybrid immunoglobulins
Assigned to Genentech Inc · Expires 2007-01-03 · 19y expired
What this patent protects
Novel peptides are provided, together with methods for making and using them, and nucleic acids encoding them. These peptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.
USPTO Abstract
Novel peptides are provided, together with methods for making and using them, and nucleic acids encoding them. These peptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.